Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 165

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1B
Chunk 165
---
holders who are beneficial owners but whose shares are held in street
name by brokers and other nominees.

Recent Sales of Unregistered Securities

 None.

Company Purchases of Equity Securities

None.

Dividends

The Company has not declared or
paid any cash dividends on its Common Stock and does not intend to declare or pay any cash dividends in the foreseeable future. The payment
of dividends, if any, is within the discretion of the Board and will depend on the Company’s earnings, if any, its capital requirements
and financial condition and such other factors as the Board may consider.

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations

The following discussion of
our financial condition and results of operations should be read in conjunction with our financial statements, and the related notes to
those statements included elsewhere in this report. In addition to the historical financial information, the following discussion and
analysis contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those
anticipated in these forward-looking statements.

Our Business

Lunai
Bioworks Inc. operates through three subsidiaries, Renovaro Biosciences,
Renovaro Cube and BioSymetrics Inc. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace
Systems B.V., which were acquired on February 13, 2024. BioSymetrics Inc. refers to BioSymetrics Inc. and its wholly owned subsidiary
BioSymetrics Corp., which were acquired on April 8, 2025.

Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers.
As a result of our acquisition of GEDi Cube Intl on February 13, 2024 and BioSymetrics Inc. on April 8, 2025, we have shifted the Company’s
primary focus and resources to the development of the GEDi Cube Intl and BioSymetrics Inc. technologies.

To date, our operations have been
funded by sales of our securities and debt financing. We have never generated any sales revenue and we expect this to continue until our
products are approved for marketing in the United States and/or Europe. Even if we are successful in having our products approved